Literature DB >> 18381958

Evaluation of D-methionine as a novel oral radiation protector for prevention of mucositis.

Saleha B Vuyyuri1, Daniel A Hamstra, Divya Khanna, Christin A Hamilton, Sonja M Markwart, Kathleen C M Campbell, Prasad Sunkara, Brian D Ross, Alnawaz Rehemtulla.   

Abstract

PURPOSE: Oral mucositis is a common acute morbidity associated with radiation and/or chemotherapy treatment for cancer. D-Methionine (D-Met), the dextro-isomer of the common amino acid l-methionine, has been documented to protect normal tissues from a diverse array of oxidative insults. EXPERIMENTAL
DESIGN: We evaluated if D-Met could selectively prevent radiation-induced oral mucositis using in vitro cell culture models as well as an in vivo model of radiation injury to the oral mucosa in C3H mice.
RESULTS: Unlike free-radical scavengers, which protected both normal and transformed tumor cells in vitro from radiation-induced cell death, treatment with d-Met in culture protected nontransformed primary human cells from radiation-induced cell death (protective factor between 1.2 and 1.6; P<0.05) whereas it did not confer a similar protection on transformed tumor cells. D-Met treatment also provided significant protection to normal human fibroblasts, but not to tumor cell lines, from radiation-induced loss of clonogenicity (protection factor, 1.6+/-0.15). D-Met treatment did not alter DNA damage (as measured by histone phosphorylation) following irradiation but seemed to selectively mitigate the loss of mitochondrial membrane potential in nontransformed cells, whereas it did not provide a similar protection to tumor cells. Tumor control of implanted xenografts treated with radiation or concurrent cisplatin and radiation was not altered by D-Met treatment. Pharmacokinetics following administration of a liquid suspension of D-Met in rats showed 68% bioavailability relative to i.v. administration. Finally, in a murine model of mucositis, a dose-dependent increase in protection was observed with the protective factor increasing from 1.6 to 2.6 over a range of oral D-Met doses between 200 and 500 mg/kg (P<0.0003).
CONCLUSIONS: D-Met protected normal tissues, but not tumor cells, in culture from radiation-induced cell death; it also protected normal cells from radiation-induced mucosal injury in a murine model but did not alter tumor response to therapy. Further studies on the use of D-Met to protect from oral mucositis are warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18381958     DOI: 10.1158/1078-0432.CCR-07-1954

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

1.  Pharmacological protection from radiation ± cisplatin-induced oral mucositis.

Authors:  Ana P Cotrim; Masanobu Yoshikawa; Abraham N Sunshine; Changyu Zheng; Anastasia L Sowers; Angela D Thetford; John A Cook; James B Mitchell; Bruce J Baum
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-22       Impact factor: 7.038

Review 2.  One-carbon metabolism and ionizing radiation: a multifaceted interaction.

Authors:  Isabelle R Miousse; Julia Tobacyk; Stepan Melnyk; S Jill James; Amrita K Cheema; Marjan Boerma; Martin Hauer-Jensen; Igor Koturbash
Journal:  Biomol Concepts       Date:  2017-05-24

3.  D-methionine protects against cisplatin-induced neurotoxicity in the hippocampus of the adult rat.

Authors:  Sneha Hinduja; Kari Suzanne Kraus; Senthilvelan Manohar; Richard J Salvi
Journal:  Neurotox Res       Date:  2014-12-09       Impact factor: 3.911

Review 4.  Review of preclinical studies on treatment of mucositis and associated pain.

Authors:  C T Viet; P M Corby; A Akinwande; B L Schmidt
Journal:  J Dent Res       Date:  2014-06-18       Impact factor: 6.116

5.  Dose-dependent protection on cisplatin-induced ototoxicity - an electrophysiological study on the effect of three antioxidants in the Sprague-Dawley rat animal model.

Authors:  Guiscardo Lorito; Stavros Hatzopoulos; Göran Laurell; Kathleen C M Campbell; Joseph Petruccelli; Pietro Giordano; Krzysztof Kochanek; Lech Sliwa; Alessandro Martini; Henryk Skarzynski
Journal:  Med Sci Monit       Date:  2011-08

6.  Role of bone marrow-derived monocytes/macrophages in the repair of mucosal damage caused by irradiation and/or anticancer drugs in colitis model.

Authors:  Junji Takaba; Yuji Mishima; Kiyohiko Hatake; Tadashi Kasahara
Journal:  Mediators Inflamm       Date:  2011-01-04       Impact factor: 4.711

Review 7.  Mechanism-based management for mucositis: option for treating side effects without compromising the efficacy of cancer therapy.

Authors:  Youngjoo Kwon
Journal:  Onco Targets Ther       Date:  2016-04-05       Impact factor: 4.147

8.  Protective Effect of D-Methionine on Body Weight Loss, Anorexia, and Nephrotoxicity in Cisplatin-Induced Chronic Toxicity in Rats.

Authors:  Ming-Tai Lin; Jiunn-Liang Ko; Te-Chung Liu; Pei-Tsen Chao; Chu-Chyn Ou
Journal:  Integr Cancer Ther       Date:  2018-02-11       Impact factor: 3.279

9.  D-Methionine Ameliorates Cisplatin-Induced Muscle Atrophy via Inhibition of Muscle Degradation Pathway.

Authors:  Ching-Te Wu; Jiuan-Miaw Liao; Jiunn-Liang Ko; Yao-Ling Lee; Hui-Yi Chang; Cheng-Hsi Wu; Chu-Chyn Ou
Journal:  Integr Cancer Ther       Date:  2019 Jan-Dec       Impact factor: 3.279

10.  D-methionine alleviates cisplatin-induced mucositis by restoring the gut microbiota structure and improving intestinal inflammation.

Authors:  Cheng-Hsi Wu; Jiunn-Liang Ko; Jiuan-Miaw Liao; Shiang-Suo Huang; Meei-Yn Lin; Ling-Hui Lee; Li-Yu Chang; Chu-Chyn Ou
Journal:  Ther Adv Med Oncol       Date:  2019-02-12       Impact factor: 8.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.